FRANKFURT (Reuters) - Bayer said on Tuesday it had secured the rights to an experimental breast cancer drug developed by U.S. biotech firm Systems Oncology LLC in a deal worth up to $370 million.
Systems Oncology will receive $25 million upfront and up to $345 million in payments that are contingent on development and commercial achievements, as well as royalties on future global net sales, Bayer said in a statement.
The compound called ERSO, which has yet to be tested on humans, is designed to treat a common type of breast cancer known as estrogen receptor-positive (ER+).
Reporting by Ludwig Burger; Editing by Michelle Adair
Our Standards: The Thomson Reuters Trust Principles.